Surgical Innovations Share Discussion Threads

[buywell3] 24/3/2018 17:04

Elemental Healthcare are selling in effect as our own UK Distributor , the last newly released SUN product/s

YelloPort Plus
The YelloPort Plus Laparoscopic Trocar system is a high-quality, cost effective, semi-disposable alternative to expensive and wasteful Disposable Trocars. Read More...

YelloPort Elite
Universal Seal Trocar System




It would seem that this type of product has a place and a market in the USA and other countries





I was expecting some news of two additions to this range of products and perhaps the announcement of a Distributor or two perhaps for the USA and maybe Japan to sell them for us.


I realize for a small company like SUN getting the RIGHT Distributor signed up is absolutely KEY to success ... which is IMO one of the main reasons SUN bought Elemental Healthcare , another being to identify new product requirements that SUN could manufacture.


I wonder if the next SUN acquisition will be perhaps a foreign based Distributor ?

Higher margins could then be obtained for the sale of the SUN Trocar ranges plus new clients and other sales opportunities.

Instead of acquiring another manufacturer of the devices themselves which can be somewhat labour intensive headcount wise.

I reckon at this point my gut is lending more towards another Distributor by 60/40%

There could perhaps, then be some big advantages down the road from doing such an acquisition of a successful foreign Distributor , maybe one that SUN knew for example like they did Elemental Healthcare.

See my previous posts

So soon I hope to read an RNS regarding news related to :

13 September 2017

Half-year Report

Interim results for the six months ended 30 June 2017


''In the first half of the year, we progressed from beta trials to full product release of the initial stages of the YelloPort Elite port access range, and further follow-on products are now expected to be available around the end of the year. We have also met with added complexity in transferring and expanding our range of single use instruments arising from the acquisition of the laparoscopic business and assets of Surgical Dynamics Limited in November 2016. We have transferred all of the manufacturing equipment to Leeds and expect application to be made for CE mark at the end of 2017, with beta trials of the products commencing in early 2018.''


Surgical Innovations says trading in line
Mon, 26th June 2017 - 06:24

''"Product innovation continues to be a priority, with focus on the further development of the YelloPort Elite range, our next generation Resposable port access system and the launch of further products to enhance our ranges of retraction and ligation solutions.''




Final results for the year ended 31 December 2016
14 Mar 2017 07:00:10

''The greater emphasis placed on new product introduction culminated in the launch of the Yelloport ™ Elite range in the final quarter of 2016, this will be followed by further additions to this range in Q2 2017 as well as two more projects launching before the end of H1. The Group is excited to be able to offer these products to the market and remains committed to expanding the portfolio of products available further in 2017 and beyond. ''


The next news I trust will maintain the SUN Chart going ahead on its present course ; trajectory upwards towards 5.5p and beyond by the year end IMO

[meijiman] 19/3/2018 12:16

Lots of recent press articles calling for more laparoscopic surgery for weight loss. One today saying it should be a procedure carried out on teens as a means of getting the weight off.Think you would be better off eating less and/or doing more exercise.

[buywell3] 19/3/2018 11:29

The 10M GDP by end of 2024 for LiquiBand® Fix8™ is IMO what could be expected for sales related to Hernia operations using MIS.

Approval in the USA market for AMS means that the size of their sales of the device for Hernia MIS operations probably triples from that it is now.

Active new marketing will push AMS sales of LiquiBand® Fix8™ ahead in the EU and the ROW from this year.



However


There is NEW sales for SUN for LiquiBand® Fix8™ in the MIS área for other NEW ´´other laparoscopic surgical applications ´´


Note the plural ... so probably two or maybe three new MIS operations OTHER tan Hernia operations for which AMS plan to use LiquiBand® Fix8™

The potential therefore of the market size worldwide for this device is now looking like it could possibly go north of 15M plus by the end of 2024

This is the date when sales rights reverts back to SUN




From AMS results last week:-

In R&D, we are also working on broadening the claims on the use of the device for hernia mesh fixation as well as for a number of other laparoscopic surgical applications

[lurki0] 17/3/2018 16:04

Buywell - thanks for that. Good to know.

[buywell3] 17/3/2018 13:34

I should add that re my previous post that as AMS plan to spend 3M GDP to get USA market approval in 2020 ... IMO this means AMS plan to get their money back PLUS another 3M GDP before the 10 year deal they signed with SUN for the exclusive sales rights for Fix8 ends in 2024.

SUN got the Fix8 device approved in 2014

Surgical Innovations

CE Approval for hernia mesh fixation device


RNS Number : 4114I

Surgical Innovations Group PLC

30 May 2014











Press Release

30 May 2014




Surgical Innovations Group plc



("SI" or the "Group" or the "Company")



CE Approval for hernia mesh fixation device



Surgical Innovations Group plc (AIM: SUN), a leading creator of innovative medical technology addressing unmet clinical needs in minimally invasive surgery, is pleased to announce that the cyanoacrylate adhesive device for hernia mesh fixation, developed for Advanced Medical Solutions Group Plc ("AMS"), under the terms of a Development and Pre-Supply Agreement entered into in September 2011, has now received CE approval.



The device, branded and marketed by AMS as LiquiBand® Fix 8™, can accurately deliver individual drops of cyanoacrylate adhesive internally within the body, giving the surgeon precision and control for the first time. The accurate, laparoscopic application of adhesives to attach hernia meshes is expected to reduce surgical complications, in particular the potential pain associated with the use of tacks and staples, thereby improving the patient experience and reducing healthcare costs overall.



Graham Bowland, Chief Executive Officer of Surgical Innovations, commented: "The CE approval is further testament to the innovative talent and ability within the SI design team. Once again SI has demonstrated its core competency of developing laparoscopic instrumentation to meet the clinical need. SI remains committed to providing AMS with the required clinical support to ensure the successful adoption of LiquiBand® Fix 8™."



buywell3 adds:

This has now been modified by SUN recently , so that it can be used for additional applications at the time of the hernia operation and new ones.

I posted on this last year on this thread.

Sales of the newly improved Fix8 should start to push ahead as of 2018

By 2024 IMO Fix8 sales for AMS will exceed 10M GDP

SUN should be getting around 3.5M GDP a year then from the deal


What will AMS do at the end of the 10 year deal ? 30th May 2024


This is what you investors must ask yourselves









Agreement with Surgical Innovations Group


RNS Number : 3798N

Advanced Medical Solutions Grp PLC

01 September 2011






For immediate release: 1 September 2011



Advanced Medical Solutions Group plc

(“AMS” or the “Company”;)



Development and Pre-Supply Agreement signed with Surgical Innovations Group plc



Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, today announces that it has signed a Development and Pre-Supply Agreement (“the Agreement”) with Surgical Innovations Group plc (“Surgical Innovations”) (AIM: SUN), for the development and supply of a novel device for internal application of adhesives and sealants.



Under the terms of the Agreement, Surgical Innovations will develop and retain the intellectual property rights for a unique applicator to deliver accurately, individual drops of adhesive or sealant internally within the body, accessed via a minimally invasive surgical port site. In return for the exclusive rights to this applicator for the internal application of adhesives and sealants, AMS has agreed to purchase all of its requirements for the approved new applicator from Surgical Innovations for a period of ten years.



The development of the internal applicator is a key step in extending the Company’s expertise in adhesives and sealants from purely topical applications to also addressing clinical needs inside the body. AMS has previously highlighted that the first target internal application would be the hernia mesh fixation market which is currently served by sutures, staples and tacks. This new internal applicator, together with the Company’s adhesives, will allow AMS to address this important market with reduced surgical complications.



Commenting on this announcement, Chris Meredith, Chief Executive Officer of AMS said:



“This agreement combines our formulation and regulatory expertise with Surgical Innovations’ applicator design and manufacturing expertise to introduce a new product to a global market for internal sealants that is now in excess of US$600 million. As we have previously indicated, an integral part of our tissue sealant and adhesives R&D is focused on moving our product range more towards the Operating Room, including internal applications. In this regard, we are optimistic that our partnership with Surgical Innovations will give us a market leading product, targeting the hernia mesh fixation market, which should be available for launch in 2013.”

[bashor] 16/3/2018 14:49

I should add I still hold 70% of my original holding and am holding medium term for 6p, just saw a new recovery play in the form of GNC that looked too tempting and it pays a dividend

[buywell3] 16/3/2018 14:45

Looks like an improvement in sales to AMS soon



Hernia Mesh Fixation device - LiquiBand® Fix8™

LiquiBand® Fix 8™ is used to hold hernia meshes in place within the body instead of tacks and staples. This accurate laparoscopic application of adhesive is expected to both reduce surgical complications and reduce the potential pain associated with the use of tacks and staples. It also provides the ability to attach mesh in areas where tacks and staples cannot be applied, helping to improve the patient experience and surgical outcomes.

As reported at the half year, sales growth of LiquiBand® Fix8™ has been restricted due to design enhancements we have made following surgeon feedback. Further feedback has been received on the updated device and modifications have been completed. We have chosen not to actively promote the device while the modifications were ongoing, nevertheless sales increased by 3% to £1.7 million (2016: £1.7 million) and 1% at constant currency. We expect to see a return to sales growth this year.



At present, the device is approved for use within Europe and those markets that accept European approval standards. We have started the process to get LiquiBand® Fix8™ approved in the US market. This necessitates a full Pre Market Approval (PMA) involving clinical trials with patient enrolment expected to start in mid 2018 and enrolment completing by the end of the year. We expect the total cost of completing the approval process will be around £3 million with the majority of the spend being incurred in 2018 and 2019.



In R&D, we are also working on broadening the claims on the use of the device for hernia mesh fixation as well as for a number of other laparoscopic surgical applications and developing a device suitable for hernia mesh fixation in open surgery which we expect to launch in Europe in the first half of 2019.

[meijiman] 16/3/2018 14:36

Well done.

[bashor] 16/3/2018 14:14

3.88 today for 500K

[meijiman] 16/3/2018 14:02

What you getting -tad over 3.8p?

[bashor] 16/3/2018 13:11

Plenty of sells not showing as sells, I’ve moved quite a few over the last 2 days and the price has held up well

[meijiman] 16/3/2018 13:08

What sells are these?

[bashor] 16/3/2018 12:56

Someone is happy to mop up all the sells, liquidity seems fairly good at the moment

[jmf69] 16/3/2018 09:05

hTtps://www.insidermedia.com/insider/yorkshire/more-acquisitions-on-the-cards-for-surgical-innovations

[jmf69] 15/3/2018 15:52

John - I think ultimately if someone came in and offered a good price for the business, then it would be sold but I think that is a few years away yet. All imho.

[john148] 15/3/2018 15:45

JM69. I see it the other way round with it being on another company`s watch list.Always thought AMS would be a good tie up thats why I bought their shares.

[jmf69] 14/3/2018 19:26

It's been a bit of a rollercoaster but the company is a different beast now with a much better leadership team and very ambitious plans. I'm quietly confident for the year and wouldn't be surprised to see further acquisitions if it's the right fit.

[gbh2] 14/3/2018 18:59

7th July 1998 when I purchased my first lot of these @ 4p a share :))

[jmf69] 14/3/2018 18:32

Expecting to break through 5p this year with the steady as she goes approach with estimated revenues to exceed 13m gbp

[jmf69] 13/3/2018 15:26

Nigel Rogers ups his stake at 3.99

[romeike] 13/3/2018 12:34

The important thing is that with the acquisition completed the associated risks are behind us and SUN can start reaping the full benefits of what is looking like a successful purchase with a nice increase in revenues. With the NHS looking to clear the backlog of operations the dip in cashflow over winter should be more delayed revenue than lost revenue.

[jmf69] 13/3/2018 08:12

Increasing revenue and profitability should lead to a positve net cash position before the end of the year. Also happy to hold.

[bashor] 13/3/2018 08:11

Agreed absolutely no reason to sell, a small correction followed be a good recovery later in the year hopefully

[kenone] 13/3/2018 08:07

Jam tomorrow then. No reason to sell though . Will stick with it & hope for progress this year.

[lurki0] 13/3/2018 08:07

Since "Headwinds" relates to the cancellation of ops in the NHS owing to winter pressures I can live with that. As is explained, at the time of writing ops are now returning to normal rates. This is a company still in turnaround mode whose board evidently know where it wants to go and is laying the foundations for growth and creation of value. I am rather comforted by the "warts and all" tone of the report. Clearly 2018 is going to be a crucial, hopefully transformational year. Happy to hold.